Home > News > Clinical trials put dendrimers on course for treating HIV
September 24th, 2003
Clinical trials put dendrimers on course for treating HIV
They might be nano’s artificial molecule, but dendrimers are taking real steps toward fighting HIV and sexually transmitted diseases in women. Starpharma Pooled Development Ltd. of Melbourne, Australia, gained approval in July from the U.S. Food and Drug Administration to start human trials of VivaGel, a dendrimer-based topical gel designed to prevent or reduce disease transmission during sexual intercourse. It’s the first dendrimer – and defined nanostructure – cleared for clinical testing, according to John Raff, Starpharma’s chief executive.
Cloaked DNA nanodevices survive pilot mission: Successful foray opens door to virus-like DNA nanodevices that could diagnose diseased tissues and manufacture drugs to treat them April 22nd, 2014
Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014
Amino-functionalized carbon nanotubes act as a carrier for nerve growth factor April 21st, 2014
Newly-Produced Bone Cement Able to Carry Medicine April 21st, 2014